MX346865B - Vacuna de virus de varicela zoster. - Google Patents

Vacuna de virus de varicela zoster.

Info

Publication number
MX346865B
MX346865B MX2012004471A MX2012004471A MX346865B MX 346865 B MX346865 B MX 346865B MX 2012004471 A MX2012004471 A MX 2012004471A MX 2012004471 A MX2012004471 A MX 2012004471A MX 346865 B MX346865 B MX 346865B
Authority
MX
Mexico
Prior art keywords
virus vaccine
zoster virus
varicella zoster
vzv
adjuvant
Prior art date
Application number
MX2012004471A
Other languages
English (en)
Inventor
Stephenne Jean
Jules Hanon Emmanuel
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34430592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346865(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX346865B publication Critical patent/MX346865B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La presente invención se refiere a el uso de un antígeno gE de VZV en la preparación de un medicamento para la administración concomitante o secuencial con un VZV vivo atenuado para prevenir o disminuir la severidad de neuralgia por herpes zóster y/o post-herpética en individuos en riegos de dichas enfermedades en donde el antígeno gE de VZV es el antígeno gE truncado para eliminar la región de ancla C-terminal, y, el antígeno de VZV se suministra con un adyuvante que comprende 3D-MPL, QS21 y liposomas que comprende colesterol.
MX2012004471A 2005-03-03 2006-03-01 Vacuna de virus de varicela zoster. MX346865B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0504436.7A GB0504436D0 (en) 2005-03-03 2005-03-03 Vaccine
PCT/EP2006/002070 WO2006094756A2 (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine

Publications (1)

Publication Number Publication Date
MX346865B true MX346865B (es) 2017-04-04

Family

ID=34430592

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2007010626A MX2007010626A (es) 2005-03-03 2006-03-01 Vacuna de virus de varicela zoster.
MX2012004471A MX346865B (es) 2005-03-03 2006-03-01 Vacuna de virus de varicela zoster.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2007010626A MX2007010626A (es) 2005-03-03 2006-03-01 Vacuna de virus de varicela zoster.

Country Status (35)

Country Link
US (3) US20080171079A1 (es)
EP (4) EP2301955B1 (es)
JP (2) JP5420842B2 (es)
KR (2) KR20140006115A (es)
CN (2) CN101189254B (es)
AR (2) AR052498A1 (es)
AU (1) AU2006222225B2 (es)
BR (1) BRPI0607840B1 (es)
CA (2) CA2600905C (es)
CY (5) CY1116108T1 (es)
DK (4) DK2281831T3 (es)
EA (1) EA011884B1 (es)
ES (4) ES2618037T3 (es)
GB (1) GB0504436D0 (es)
HK (1) HK1111427A1 (es)
HR (4) HRP20150142T1 (es)
HU (4) HUE038468T2 (es)
IL (1) IL185442A (es)
LT (4) LT2281831T (es)
LU (1) LUC00087I2 (es)
MA (1) MA29714B1 (es)
MX (2) MX2007010626A (es)
MY (1) MY148464A (es)
NL (1) NL300951I2 (es)
NO (1) NO341841B1 (es)
NZ (1) NZ561075A (es)
PE (2) PE20061287A1 (es)
PL (4) PL2281831T3 (es)
PT (4) PT2281830T (es)
SI (4) SI1858917T1 (es)
TR (2) TR201809397T4 (es)
TW (1) TWI403517B (es)
UA (1) UA94900C2 (es)
WO (1) WO2006094756A2 (es)
ZA (1) ZA200707144B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2729011A1 (en) * 2007-07-19 2009-01-22 Novavax, Inc. Varicella zoster virus-virus like particles (vlps) and antigens
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
PT2590626E (pt) 2010-07-06 2016-01-26 Glaxosmithkline Biolog Sa Lipossomas com lípidos que têm um valor de pka vantajoso para administração de arn
PT2591114T (pt) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Imunização de mamíferos de grande porte com doses baixas de arn
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
EP4066857B1 (en) 2010-08-31 2022-12-21 GlaxoSmithKline Biologicals SA Pegylated liposomes for delivery of immunogen-encoding rna
KR102162111B1 (ko) 2010-10-11 2020-10-07 노파르티스 아게 항원 전달 플랫폼
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CA2923030A1 (en) * 2013-10-03 2015-04-09 Nitto Denko Corporation Injectable vaccine composition
JP6499420B2 (ja) * 2014-11-13 2019-04-10 公益財団法人ヒューマンサイエンス振興財団 ワクチン及び感染防御キット
BE1022523B1 (fr) * 2014-12-18 2016-05-20 Glaxosmithkline Biologicals Sa Vaccination
CN107106675A (zh) * 2014-12-18 2017-08-29 葛兰素史密丝克莱恩生物有限公司 疫苗接种
BR112018008051A2 (pt) * 2015-10-22 2018-11-13 Modernatx Inc vacinas de ácido nucleico para vírus de varicella zoster (vzv)
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
IL293848A (en) 2015-11-06 2022-08-01 Adjuvance Tech Inc Triterpene saponin analogs, methods for their production, preparations containing them and their uses
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
US10874734B2 (en) 2016-11-25 2020-12-29 Mogam Institute For Biomedical Research Varicella zoster virus vaccine
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
EA038864B1 (ru) * 2016-12-26 2021-10-29 Могам Инститьют Фор Байомедикал Рисерч Вакцинная композиция против опоясывающего герпеса
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
EP3618836A4 (en) * 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENSAPONINALOGA
EP3615039A4 (en) * 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGUES
WO2018198085A1 (en) 2017-04-28 2018-11-01 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
EP3697802A4 (en) 2017-10-16 2021-11-24 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGUES
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
CN108315344A (zh) * 2018-02-14 2018-07-24 武汉博沃生物科技有限公司 Vzv糖蛋白e基因表达载体及其重组酵母菌株与应用
KR20190121956A (ko) 2018-04-19 2019-10-29 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
KR102337922B1 (ko) 2018-04-19 2021-12-09 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
UA126460C2 (uk) * 2018-05-23 2022-10-05 Моґам Інститьют Фор Байомедикал Рисерч Антигенний варіант вірусу varicella zoster і його застосування
JP2021533162A (ja) 2018-08-07 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロセス及びワクチン
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CA3114658A1 (en) * 2018-09-27 2020-04-02 Bravovax Co., Ltd Immune composition, preparation method therefor and use thereof
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
CA3142300A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
TW202128216A (zh) * 2019-12-13 2021-08-01 大陸商遠大賽威信生命科學（南京）有限公司 免疫刺激組合物及其用途
CN115210249A (zh) * 2020-02-28 2022-10-18 赛特瑞恩股份有限公司 水痘带状疱疹病毒融合蛋白以及包含该融合蛋白的免疫原性组合物
AU2021321944A1 (en) 2020-08-07 2023-04-06 Access To Advanced Health Institute Purified saponins and chromatographic process for purification of same
KR102660479B1 (ko) * 2020-09-11 2024-04-25 주식회사 유바이오로직스 수두 또는 대상포진 백신 조성물 및 이를 이용하는 방법
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
WO2023064612A2 (en) 2021-10-15 2023-04-20 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
WO2023096963A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
CN116350770A (zh) * 2021-12-28 2023-06-30 成都迈科康生物科技有限公司 一种带状疱疹疫苗制剂及其制备方法
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (es) 1974-03-12 1978-11-01
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0405867B1 (en) 1989-06-27 1995-03-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Novel compounds
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
SG90042A1 (en) * 1992-06-25 2002-07-23 Smithkline Beecham Biolog Vaccine composition containing adjuvants
DK0651789T4 (da) * 1992-07-17 2009-07-27 Merck & Co Inc Fremgangsmåde til at forebygge zoster eller lindre varicella-forbundet post-herpetisk neuralgia
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
EP0817847B2 (en) * 1995-03-23 2009-09-09 Immunex Corporation Il-17 receptor
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
PT971739E (pt) 1997-04-01 2004-12-31 Corixa Corp Composicoes aquosas de adjuvante imunologico de monofosforil lipido a
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ES2201551T3 (es) 1997-09-05 2004-03-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
CA2425358C (en) * 2000-10-18 2012-08-21 Glaxosmithkline Biologicals S.A. A vaccine composition comprising qs21, mpl, a cpg oligonucleotide and a cancer antigen
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
PE20100658A1 (es) 2010-10-23
NL300951I1 (nl) 2018-09-26
CY1116108T1 (el) 2017-02-08
HRP20180989T1 (hr) 2018-08-10
MY148464A (en) 2013-04-30
JP2013144710A (ja) 2013-07-25
JP2008531637A (ja) 2008-08-14
AU2006222225B2 (en) 2012-08-16
MX2007010626A (es) 2007-10-16
PT1858917E (pt) 2015-02-24
IL185442A (en) 2013-07-31
WO2006094756A3 (en) 2007-02-15
DK2281830T3 (en) 2017-03-20
PT2281830T (pt) 2017-02-24
ES2675054T3 (es) 2018-07-06
JP5840167B2 (ja) 2016-01-06
TW200643028A (en) 2006-12-16
LT2281831T (lt) 2018-07-10
US7939084B1 (en) 2011-05-10
TR201809397T4 (tr) 2018-07-23
UA94900C2 (uk) 2011-06-25
US20110045059A1 (en) 2011-02-24
LT2301955T (lt) 2018-07-10
NO341841B1 (no) 2018-02-05
LTC2281831I2 (lt) 2020-08-25
EA011884B1 (ru) 2009-06-30
PE20061287A1 (es) 2006-12-07
CN103028113A (zh) 2013-04-10
PT2301955T (pt) 2018-06-18
CN101189254B (zh) 2013-05-22
CA2882255A1 (en) 2006-09-14
HRP20180988T1 (hr) 2018-08-10
NO20074392L (no) 2007-11-27
EP2281830A2 (en) 2011-02-09
CN103028113B (zh) 2015-05-20
ES2618037T3 (es) 2017-06-20
SI2281830T1 (sl) 2017-03-31
EP2281830B1 (en) 2016-12-21
BRPI0607840A2 (pt) 2009-06-13
HUE038467T2 (hu) 2018-10-29
PL1858917T3 (pl) 2015-05-29
LT2281830T (lt) 2017-02-10
EP2281831A3 (en) 2011-11-16
HK1111427A1 (en) 2008-08-08
KR20070110413A (ko) 2007-11-16
EA200701632A1 (ru) 2008-02-28
HUE038468T2 (hu) 2018-10-29
CA2882255C (en) 2018-03-27
EP2301955A3 (en) 2011-11-16
HRP20170081T1 (hr) 2017-03-24
ES2675055T3 (es) 2018-07-06
CY2018025I1 (el) 2018-12-12
US20080171079A1 (en) 2008-07-17
ZA200707144B (en) 2009-11-25
KR20140006115A (ko) 2014-01-15
PL2281830T3 (pl) 2017-06-30
EP2301955B1 (en) 2018-04-18
MA29714B1 (fr) 2008-09-01
TWI403517B (zh) 2013-08-01
ES2532803T3 (es) 2015-03-31
GB0504436D0 (en) 2005-04-06
LUC00087I2 (es) 2018-11-26
NL300951I2 (nl) 2020-08-31
SI2281831T1 (en) 2018-07-31
CA2600905C (en) 2015-05-05
JP5420842B2 (ja) 2014-02-19
EP2281831B1 (en) 2018-04-18
HUE032544T2 (en) 2017-10-30
KR101357204B1 (ko) 2014-02-06
CY1118629T1 (el) 2017-07-12
IL185442A0 (en) 2008-01-06
BRPI0607840B1 (pt) 2021-06-29
DK2281831T3 (en) 2018-06-14
EP2301955A2 (en) 2011-03-30
EP2281831A2 (en) 2011-02-09
EP1858917B8 (en) 2015-05-06
PL2281831T3 (pl) 2018-08-31
AU2006222225A1 (en) 2006-09-14
WO2006094756A2 (en) 2006-09-14
CN101189254A (zh) 2008-05-28
EP2281830A3 (en) 2012-01-25
HRP20150142T1 (hr) 2015-05-22
PT2281831T (pt) 2018-06-15
DK2301955T3 (en) 2018-06-14
CA2600905A1 (en) 2006-09-14
US20110104260A1 (en) 2011-05-05
EP1858917B1 (en) 2014-12-24
TR201809393T4 (tr) 2018-07-23
AR107285A2 (es) 2018-04-18
LTPA2018012I1 (lt) 2018-11-12
SI2301955T1 (en) 2018-07-31
EP1858917A2 (en) 2007-11-28
SI1858917T1 (sl) 2015-03-31
NZ561075A (en) 2009-06-26
AR052498A1 (es) 2007-03-21
PL2301955T3 (pl) 2018-08-31
CY1120347T1 (el) 2018-12-12
CY2018025I2 (el) 2018-12-12
HUS1800038I1 (hu) 2018-10-29
CY1121211T1 (el) 2020-05-29
DK1858917T3 (da) 2015-02-02

Similar Documents

Publication Publication Date Title
MX346865B (es) Vacuna de virus de varicela zoster.
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
SG170127A1 (en) Vaccine compositions comprising a saponin adjuvant
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
WO2007024941A3 (en) Polyvalent vaccine
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2008096831A1 (ja) 癌の治療剤
MY143347A (en) Mucosal immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
WO2005120564A3 (en) Vaccine compositions and methods
WO2011075822A8 (en) Immunogenic compositions and related methods
MX2007009961A (es) Composicion adyuvante que comprende fosfato de aluminio y 3d-mpl.
AR108718A2 (es) Composición
WO2008008541A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
GB2444676A (en) Adjuvanted vaccine
AU2003255275A1 (en) Improved anthrax vaccines and delivery methods
PL1945252T3 (pl) Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
WO2007028985A3 (en) Adjuvanted vaccine
WO2009129498A3 (en) Substance p and analogs thereof as a cancer immunogenic composition adjuvant
AR103030A1 (es) Composición inmunógena
WO2007047763A3 (en) Bcr-abl vaccines and methods of use thereof
陈培善 Epicentral distribution in 2006
WO2007147518A3 (en) Use of ppd for the adjuvantation of a nucleic acid vaccine
WO2008100142A3 (en) Vaccine formulation